A report being published in The New England Journal of Medicine found that the heart surgery drug aprotinin, sold as Trasyol, poses unnecessary risks to patients and should be replaced by safer alternatives. Doctors found that the blood-clotting medication can cause kidney failure and increase the prevalence of heart attacks and strokes. Bayer disputes the finding, which will be reviewed by the Food and Drug Administration.
To read the full story in the New York Times: Doctors Urge Ending Use of Heart Surgery Drug
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.